Please assess the completion status of the following clinical trial:

Trial Title: Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status~* Currently being treated with an AI in the adjuvant setting (minimum for 8 weeks)~* AIMSS as determined by new or worsened musculoskeletal complaints following AI therapy~* Vitamin D deficiency (\<30ng/ml)~* Caucasian~Exclusion Criteria:~* Hormone replacement therapy last 6 months~* Current use or in the last 12 months of bisphosphonates~* Tamoxifen use in last 6 months~* History of kidney stones~* History of hypercalcemia/hypercalciuria or hyperthyroidism~* Paget's disease of the bone~* Current use of Digitalis/digoxin or thiazide diuretics~* Current use of vitamin D (or multivitamin) supplementation should be stopped

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin D3 (Type: EXPERIMENTAL): 1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
- Placebo (Type: PLACEBO_COMPARATOR): 1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).